ClinicalTrials.gg
Status unknownNCT03588494Updated Jul 17, 2018

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

A Phase 2/3 interventional study of concurrent chemoradiotherapy (CCRT) and Endostar for one cycle in Quality of Life, sponsored by Affiliated Hospital of North Sichuan Medical College. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-07-17.

Sponsored by Affiliated Hospital of North Sichuan Medical College · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To investigate the safety and efficacy recombinant human endostatin(endostar) durative transfusion combined with cocurrent chemoradiotherapy in advanced non-small cell lung cancer(NSCLC).

02

Conditions studied

  • Quality of Life

Keywords

  • Recombinant human endostatin
  • NSCLC
  • chemoradiotherapy
03

In context

Lead sponsor

Affiliated Hospital of North Sichuan Medical College is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male or female patients, age: 18-70 years of age
    1. Pathology was diagnosed as non-small cell lung cancer. According to the Tumor Node (TNM)stage of the 8th edition of the International Association for the Study of Lung Cancer in 2017, And the pathological stage was identified as stage IIIa-b.
    1. No previous chest radiotherapy and radiotherapy, immunotherapy or biological therapy.
    1. (ECOG) test scored 0-1.
    1. Serum ≥ 100g/L, ≥ 100 × 109/L, absolute number of neutrophils ≥ 1.5 × 109/L.
    1. Serum creatinine ≤ 1.25 times the (UNL) or ≥ 60 mL/min.
    1. Serum ≤ 1.5 times UNL, (AST) and adenosine triphosphate (ALT) ≤ 2.5 times UNL, alkaline phosphatase ≤ 5 times UNL.
    1. Forced vital capacity rate of one second()>0.8 litre.
    1. Coagulation function is normal
    1. lesions are measurable according to the Version 1.1(RECIST1.1)standard
    1. Sign the inform consent form with good compliance

Exclusion criteria

Exclusion Criteria:

    1. Carcinoid or small cell lung cancer
    1. Patients with any distant
    1. patients with previous or current , except for skin non-melanoma or carcinoma in situ in the cervix
    1. Any other disease or condition is a to chemoradiation (eg, active infection, 6 months after myocardial infarction, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmia, therapy).
    1. Pregnancy or breastfeeding women
    1. Women who may be pregnant but are unwilling to take appropriate
    1. Hereditary bleeding or coagulopathy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
318 participants (estimated)

Study arms

  • Active comparator
    concurrent chemoradiotherapy (CCRT)

    Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1~5 and 29~33. Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday~Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.

    Combination Product: concurrent chemoradiotherapy (CCRT)

  • Experimental
    W1-CCRT

    Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5~-1). Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1~5 and 29~33. Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday~Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.

    Combination Product: concurrent chemoradiotherapy (CCRT) · Drug: Endostar for one cycle

  • Experimental
    W2-CCRT

    Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5~-1 and 24~28). Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1~5 and 29~33. Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday~Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.

    Combination Product: concurrent chemoradiotherapy (CCRT) · Drug: Endostar for two cycles

Interventions

  • Combination productconcurrent chemoradiotherapy (CCRT)

    Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1~5 and 29~33. Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday~Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.

  • DrugEndostar for one cycle

    Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5~-1).

  • DrugEndostar for two cycles

    Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5~-1 and 24~28).

06

What researchers measure

Primary outcomes

  1. progression free survival (PFS)

    Evaluate the effect of chemoradiotherapy with or without recombinant human endostatin on progression free survival

    Time frame: 4 years

Secondary outcomes

  1. Overall Survival(OS)

    comparison to maintenance chemoradiotherapy alone

    Time frame: 4 years

  2. Treatment-related toxicity

    Toxicity and adverse events related to the inventions

    Time frame: 4 years

07

Study locations

1 site
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan 600000, China
    • Daiyuan Ma, M.D · Contactangenpn@gmail.com · 868172246171
    • xin hu, M.D · Principal investigator
    • xiangdong fang, M.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2018; primary completion for Sep 2019, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2018
First posted
Jul 17, 2018
StartEst.
Aug 1, 2018
Primary completionEst.
Sep 1, 2019
CompletionEst.
Sep 1, 2021
Last update
Jul 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03588494
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Responsible party
DaiYuan Ma (Director of Cancer Center, Affiliated Hospital of North Sichuan Medical College) — Principal investigator
First posted
Jul 17, 2018
Start date
Aug 1, 2018 (estimated)
Primary completion
Sep 1, 2019 (estimated)
Completion
Sep 1, 2021 (estimated)
Last update
Jul 17, 2018

Study contacts

Daiyuan Ma, M.D
Contact
angenpn@gmail.com
868172246171
Daiyuan Ma, M.D
principal investigator · Affiliated Hospital of North Sichuan Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion